US’ Fauci: US may not need AstraZeneca COVID-19 vaccine

Anil Panchal FXStreet

Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), told Reuters on Thursday that the United States may not need AstraZeneca's COVID-19 vaccine, even if it wins U.S. regulatory approval.

“The vaccine, once hailed as another milestone in the fight against the COVID-19 pandemic, has been dogged by questions since late last year, even as it has been authorized for use by dozens of countries, not including the US,” said the news.

Additional comments from Dr. Fauci mentioned, "If you look at the numbers (of doses) that we're going to be getting, the amount that you can get from J&J, from Novavax from Moderna if we contract for more, it is likely that we can handle any boost that we need, but I can't say definitely for sure."

Elsewhere chatters also grew louder suggesting the US government is working on new travel guidance for vaccinated Americans and the same will be out by Friday. However, nothing key appeared strong during the dull Good Friday markets.

Market reaction

Given the holiday in multiple Asian markets, due to the Good Friday, there was a little reaction to the news that should have ideally weighed on the sentiment. That said, S&P 500 Futures print mild gains of 0.12% by the press time.

Read: Gold Price Analysis: XAU/USD bulls probed below $1,750 amid thin holiday trade

Author

Anil Panchal

FXStreet

Anil Panchal has nearly 15 years of experience in tracking financial markets. With a keen interest in macroeconomics, Anil aptly tracks global news/updates and stays well-informed about the global financial moves and their implications.

GBP/USD: Daily gains remain capped by 1.3650

GBP/USD leaves behind Monday’s pessimism and advances marginally on Tuesday. Cable’s humble gains, however, appear to have met quite a decent resistance in the 1.3650 zone for now, in a context of a slight selling pressure hovering around the Greenback.

EUR/USD struggles to regain pace; gyrates around 1.1670

EUR/USD clinches humble gains around 1.1670 following Tuesday’s close on Wall Street. Indeed, marginal losses in the US Dollar encourages spot to set aside two dauly pullbacks in a row and maintain the 1.1700 barrier on the cross-hairs for now. Moving forward, US inflation tracked by the PCE and another revision of Q2 GDP data should keep investors entertained on Wednesday.

Gold struggles near $4,650 ahead of US PCE inflation data

Gold struggles around $4,650 early Wednesday after the previous day's two-way swings as traders await the US PCE data for cues about the Fed's interest rate path. The outlook could drive the US Dollar and the non-yielding bullion. Meanwhile, renewed hopes for a US-Iran peace deal, weak Oil prices, sliding US bond yields and diminishing odds of an immediate tightening by the Fed undermine the USD, which could likely limit Gold's downside.

Bitcoin posts strongest weekly gain since November 2024 as market activity surges

Bitcoin (BTC) has posted its strongest one-week gain since the November 2024 US presidential election, climbing 23% over the past week as spot market activity and institutional demand returned sharply, according to a Tuesday report from K33. The rally pushed Bitcoin from around $63,000 to over $80,000 by late Monday.

America’s self‑inflicted trade wound

I’m conflicted about the trade war that the U.S. has started with Canada. Let’s be clear: any representation that Canada has been taking unfair advantage of the U.S. or that they have been treating us badly for years is a bogus characterization. In reality, the shoe is on the other foot. It’s the U.S. that has been behaving badly.

Canada hits US goods with tariffs; The rate market sees a problem

On September 8, Canada begins charging its own importers 15%, 25% and 50% on roughly 700 lines of American goods. The measure is billed as dollar for dollar, and on the arithmetic of covered trade it is. What it is not is a tax on the United States.